Generalized Myasthenia Gravis Clinical Trials in Washington D.C., District of Columbia
5 recruitingWashington D.C., District of Columbia
Showing 1–5 of 5 trials
Recruiting
Phase 3
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany264 enrolled145 locationsNCT06463587
Recruiting
Phase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Immunovant Sciences GmbH231 enrolled84 locationsNCT07039916
Recruiting
Phase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Novartis Pharmaceuticals180 enrolled129 locationsNCT06744920
Recruiting
Phase 3
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Generalized Myasthenia GravisgMG
Alexion Pharmaceuticals, Inc.12 enrolled13 locationsNCT06607627
Recruiting
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.500 enrolled51 locationsNCT04202341